Provention Bio begins Phase IIa systemic lupus erythematosus trial
Provention Bio will recruit adult SLE subjects across nearly 28 centres in the US and Hong Kong for the study.

Provention Bio will recruit adult SLE subjects across nearly 28 centres in the US and Hong Kong for the study.
Early data from a small trial conducted by the University of Hong Kong has demonstrated promise for the Covid-19 treatment…
One Asian country and seven European countries are among the ten most affected list of countries with coronavirus, while more…
US-based biotechnology firm Cocrystal Pharma has signed a clinical trial agreement with Humanity & Health Research Centre in Hong Kong…
Molecular technology firm Zymergen Inc has acquired Radiant Genomics Inc, a functional metagenomics research company.
AmpliPhi Biosciences Corp plans to issue shares of its common stock in a public offering.